Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 7/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427560 | 1.00 | — | — | |
| SCHEMBL78599 | 1.00 | — | — | |
| SCHEMBL15355765 | 1.00 | — | — | |
| SCHEMBL23958 | 1.00 | — | — | |
| Hydrogen Peroxide SCHEMBL2783488 | 1.00 | — | — | |
| SCHEMBL587531 | 0.97 | — | — | |
| SCHEMBL15820001 | 0.97 | — | — | |
| Bromide SCHEMBL11723723 | 0.97 | — | — | |
| SCHEMBL587047 | 0.97 | — | — | |
| SCHEMBL16177042 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805487-B | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-113045625-B | Polypeptides as somatostatin receptor agonists and uses thereof | 成都诺和晟泰生物科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-113072617-B | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-115894617-A | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114805487-A | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-113072617-A | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-113045625-A | Polypeptide as growth hormone secretagogue receptor agonist and application thereof | 成都诺和晟泰生物科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-106581139-A | Pharmaceutical composition for curing stomach cancer and preparation method of pharmaceutical composition | 济南昊雨青田医药技术有限公司 | 2017-04-26 | — | — | CN | disclosed |
| US-20110259743-A1 | METHOD FOR DETERMINATION OF OXIDATIVE STRESS | KEIO UNIVERSITY (JP) | 2011-10-27 | — | — | US | disclosed |
| US-7964177-B2 | Method for determination of oxidative stress | KEIO UNIVERSITY (JP) | 2011-06-21 | — | — | US | disclosed |
| CN-1145695-C | Antifungal proteins | — | 2004-04-14 | — | — | CN | disclosed |
| US-20020025925-A1 | Combination therapy | WOOD LARS MICHAEL (GB) | 2002-02-28 | — | — | US | disclosed |
| EP-0936918-B1 | COMBINATION THERAPY FOR TREATMENT OF ARTHRITIC DISEASES | BRITISH BIOTECH PHARM (GB) | 2002-02-27 | — | — | EP | disclosed |
| EP-0936918-A1 | COMBINATION THERAPY FOR TREATMENT OF ARTHRITIC DISEASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| CN-1204366-A | Antifungal protein | ZENECA LTD (GB) | 1999-01-06 | — | — | CN | disclosed |
| WO-1998011908-A1 | COMBINATION THERAPY FOR TREATMENT OF ARTHRITIC DISEASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-26 | — | — | WO | disclosed |
| WO-1994022910-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993007170-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025925-A1 | Combination therapy | TIMP3, MMP3, MMP17 | SLC1A2 2251/4885SLC1A3 2410/4885SLC1A1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.